Physicians' Academy for Cardiovascular Education

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

ESC 2017 - Barcelona

3' education - Aug. 27, 2017

ESC 2017 Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician. Lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.


Paul M Ridker, MD - Brigham and Women's Hospital, Boston, MA, USA

The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: